Meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment, 14844-14845 [2024-04197]

Download as PDF 14844 Federal Register / Vol. 89, No. 41 / Thursday, February 29, 2024 / Notices would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)— RFA–IP–24–017, Collaborative Research on Influenza and Other Respiratory Pathogens in South Africa; and RFA–IP– 24–081, Public Health Epidemiology, Prevention and Control of Influenza and Other Respiratory Pathogens in China. Date: May 17, 2024. Time: 10 a.m.–5 p.m., EDT. Place: Videoconference. Agenda: To review and evaluate grant applications. For Further Information Contact: Gregory Anderson, M.S., M.P.H., Scientific Review Officer, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–6, Atlanta, Georgia 30329–4027. Telephone: (404) 718–8833; Email: GAnderson@cdc.gov. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Occupational Safety and Health (NIOSH). Dates: June 4–5, 2024. Times: 11 a.m.–5 p.m., EDT. Place: Teleconference. Agenda: The meeting will convene to address matters related to the conduct of Study Section business and for the Study Section to consider safety and occupational health-related grant applications. For Further Information Contact: Michael Goldcamp, Ph.D., Scientific Review Officer, Office of Extramural Programs, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 1095 Willowdale Road, Morgantown, West Virginia 26506. Telephone: (304) 285–5951; Email: MGoldcamp@cdc.gov. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–04200 Filed 2–28–24; 8:45 am] Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2024–04198 Filed 2–28–24; 8:45 am] BILLING CODE 4163–18–P Centers for Disease Control and Prevention DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment Centers for Disease Control and Prevention AGENCY: khammond on DSKJM1Z7X2PROD with NOTICES Notice of Closed Meeting In accordance with 5 U.S.C. 1009(d), the Centers for Disease Control and Prevention (CDC) announces the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. Name of Committee: Safety and Occupational Health Study Section (SOHSS), National Institute for VerDate Sep<11>2014 16:39 Feb 28, 2024 Jkt 262001 Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of meeting. In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) and the Health Resources and Services Administration (HRSA) announce the following meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHAC). This meeting is open to the public, limited only by the number of audio and web conference lines (1,000 lines are available). Time will be available for public comment (registration is required to provide oral comment). SUMMARY: PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 The meeting will be held on April 9 and 10, 2024, from 9 a.m. to 4:30 p.m., EDT. Written comments must be submitted by April 19, 2024. Registration to make oral comments must be submitted by March 26, 2024. ADDRESSES: The telephone access number is 1–669–254–5252, Webinar ID: 160 972 1316, and the Passcode is 08044152. The web conference access is https://cdc.zoomgov.com/j/1609721316? pwd=cUVqdUp5dlBNaDhhWER rcWdXUk9yUT09, and the Passcode is dx%cJGp3. The number of available audio and web conference lines is 1,000. FOR FURTHER INFORMATION CONTACT: Marah Condit, M.S., Committee Management Lead, Office of Policy, Planning, and Partnerships, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US8–6, Atlanta, Georgia 30329–4027. Telephone: (404) 639–3423; Email: nchhstppolicy@ cdc.gov. SUPPLEMENTARY INFORMATION: Purpose: The CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHAC) is charged with advising the Secretary of Health and Human Services; the Director, Centers for Disease Control and Prevention (CDC); and the Administrator, Health Resources and Services Administration (HRSA), regarding objectives, strategies, policies, and priorities for HIV, viral hepatitis, and STD prevention and treatment efforts including (1) surveillance; (2) epidemiologic, behavioral, health services, and laboratory research; (3) identification of policy issues and opportunities related to prevention and treatment including but not limited to professional education, healthcare delivery, social determinants of health, research, and prevention and treatment services; (4) strategic issues influencing the ability of CDC and HRSA to fulfill their missions; (5) development and implementation of federal programs focused on prevention and treatment; and (6) provide support to the agencies in their response to emerging health needs. Matters to be Considered: The agenda will include discussions on (1) syndemic approach to testing, (2) using prescription data to support the HIV care continuum, (3) HIV and aging, (4) an update on DoxyPEP, (5) advancing diagnosis of hepatitis C virus infection, (6) an update from the Long-Acting Injectable Workgroup, (7) an update from the Community Partnerships Workgroup, (8) an update from the DATES: E:\FR\FM\29FEN1.SGM 29FEN1 Federal Register / Vol. 89, No. 41 / Thursday, February 29, 2024 / Notices Workforce Workgroup, and (9) an update from the Presidential Advisory Council on HIV/AIDS. Agenda items are subject to change as priorities dictate. Public Participation Written Public Comment: Members of the public are welcome to submit written comments in advance of the meeting. Written comments must be submitted by emailing nchhstppolicy@ cdc.gov with subject line ‘‘Spring CHAC Public Comment Registration’’ by April 19, 2024. Oral Public Comment: Individuals who would like to make an oral comment during the public comment period must register by emailing nchhstppolicy@cdc.gov with subject line ‘‘Spring CHAC Public Comment Registration’’ by March 26, 2024. The public comment period is on April 9, 2024, at 3:45 p.m., EDT. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–04197 Filed 2–28–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Meeting of the Advisory Board on Radiation and Worker Health, Subcommittee for Procedure Reviews, National Institute for Occupational Safety and Health Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of meeting. AGENCY: In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting for the Subcommittee on Procedures Reviews (SPR) of the Advisory Board on Radiation and Worker Health (ABRWH or the Advisory Board). This meeting is open to the khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 16:39 Feb 28, 2024 Jkt 262001 public, but without a public comment period. The public is also welcomed to listen to the meeting by joining the audio conference (information below). The audio conference line has 150 ports for callers. DATES: The meeting will be held on March 14, 2024, from 11 a.m. to 4:30 p.m., EDT. Written comments must be received on or before March 7, 2024. ADDRESSES: You may submit comments by mail to: Rashaun Roberts, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 1090 Tusculum Avenue, MS C–24, Cincinnati, Ohio 45226. Meeting Information: Audio Conference Call via FTS Conferencing. The USA toll-free dial-in number is 1– 866–659–0537; the pass code is 9933701. FOR FURTHER INFORMATION CONTACT: Rashaun Roberts, Ph.D., Designated Federal Officer, National Center for Occupational Safety and Health, Centers for Disease and Prevention, 1090 Tusculum Avenue, Mailstop C–24, Cincinnati, Ohio 45226, Telephone: (513) 533–6800; Email: ocas@cdc.gov. SUPPLEMENTARY INFORMATION: Background: The Advisory Board on Radiation and Worker Health (ABRWH or the Advisory Board) was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Advisory Board include providing advice on the development of probability of causation guidelines that have been promulgated by the Department of Health and Human Services (HHS) as a final rule; advice on methods of dose reconstruction, which have also been promulgated by HHS as a final rule; advice on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program; and advice on petitions to add classes of workers to the Special Exposure Cohort. In December 2000, the President delegated responsibility for funding, staffing, and operating the Advisory Board to HHS, which subsequently delegated this authority to CDC. NIOSH implements this responsibility for CDC. The charter was issued on August 3, 2001, renewed at appropriate intervals, and rechartered under Executive Order 14109 on March 22, 2022, and will terminate on March 22, 2024. PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 14845 Purpose: The Advisory Board is charged with (a) providing advice to the Secretary, HHS, on the development of guidelines under Executive Order 13179; (b) providing advice to the Secretary, HHS, on the scientific validity and quality of dose reconstruction efforts performed for this program; and (c) upon request by the Secretary, HHS, advise the Secretary on whether there is a class of employees at any Department of Energy facility who were exposed to radiation but for whom it is not feasible to estimate their radiation dose, and on whether there is reasonable likelihood that such radiation doses may have endangered the health of members of this class. The ABWRH Subcommittee on Procedure Reviews (SPR) is responsible for overseeing, tracking, and participating in the reviews of all procedures used in the dose reconstruction process by the NIOSH Division of Compensation Analysis and Support (DCAS) and its dose reconstruction contractor (Oak Ridge Associated Universities—ORAU). Matters to be Considered: The agenda will include discussions on the following: 1. Carry-over items from November 16, 2023, SPR Meeting, including a. DCAS–PER–040 ‘‘Mallinckrodt TBD Revisions,’’ b. Peeks Street review—NIOSH, and c. ANL–W TBD revision—review application of ORAUT–RPRT–0097. 2. Newly-issued SC&A reviews, including a. ORAUT– RPRT–0071 ‘‘External Dose Coworker Methodology,’’ b. ORAUT–RPRT–0084 ‘‘Two-Count Filter Method for Measurement of Thoron Progeny in Air,’’ c. DCAS–PER–047 ST4 ‘‘GJOO,’’ d. ‘‘Amchitka Island template,’’ e. ‘‘Albuquerque Operations Office template,’’ f. DCAS–PER–068 ‘‘Electro Metallurgical Co,’’ g. DCAS–PER–070 ‘‘Nuclear Metals Inc.,’’ h. DCAS–PER– 072 ‘‘Seymour Specialty Wiring Co,’’ i. ORAUT–RPRT–0060 ‘‘Neutron Dose from Highly Enriched Uranium.’’; 3. PERs previously identified as not needing a review; 4. Preparation for April 2024 Full ABRWH Meeting: Review of technical guidance documents ready for full Board approval; 5. Newly-Issued Guidance and Supplemental Topics. Agenda items are subject to change as priorities dictate. For additional information, please contact Toll Free 1 (800) 232–4636. Meeting Information: Audio Conference Call via FTS Conferencing. The USA toll-free dial-in number is 1– 866–659–0537; the pass code is 9933701. Public Participation Written Public Comment: The public is welcome to submit written comments E:\FR\FM\29FEN1.SGM 29FEN1

Agencies

[Federal Register Volume 89, Number 41 (Thursday, February 29, 2024)]
[Notices]
[Pages 14844-14845]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-04197]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Meeting of the CDC/HRSA Advisory Committee on HIV, Viral 
Hepatitis and STD Prevention and Treatment

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Advisory Committee Act, the 
Centers for Disease Control and Prevention (CDC) and the Health 
Resources and Services Administration (HRSA) announce the following 
meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and 
STD Prevention and Treatment (CHAC). This meeting is open to the 
public, limited only by the number of audio and web conference lines 
(1,000 lines are available). Time will be available for public comment 
(registration is required to provide oral comment).

DATES: The meeting will be held on April 9 and 10, 2024, from 9 a.m. to 
4:30 p.m., EDT.
    Written comments must be submitted by April 19, 2024. Registration 
to make oral comments must be submitted by March 26, 2024.

ADDRESSES: The telephone access number is 1-669-254-5252, Webinar ID: 
160 972 1316, and the Passcode is 08044152. The web conference access 
is https://cdc.zoomgov.com/j/1609721316?pwd=cUVqdUp5dlBNaDhhWERrcWdXUk9yUT09, and the Passcode is 
dx%cJGp3. The number of available audio and web conference lines is 
1,000.

FOR FURTHER INFORMATION CONTACT: Marah Condit, M.S., Committee 
Management Lead, Office of Policy, Planning, and Partnerships, National 
Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for 
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US8-6, 
Atlanta, Georgia 30329-4027. Telephone: (404) 639-3423; Email: 
[email protected].

SUPPLEMENTARY INFORMATION: 
    Purpose: The CDC/HRSA Advisory Committee on HIV, Viral Hepatitis 
and STD Prevention and Treatment (CHAC) is charged with advising the 
Secretary of Health and Human Services; the Director, Centers for 
Disease Control and Prevention (CDC); and the Administrator, Health 
Resources and Services Administration (HRSA), regarding objectives, 
strategies, policies, and priorities for HIV, viral hepatitis, and STD 
prevention and treatment efforts including (1) surveillance; (2) 
epidemiologic, behavioral, health services, and laboratory research; 
(3) identification of policy issues and opportunities related to 
prevention and treatment including but not limited to professional 
education, healthcare delivery, social determinants of health, 
research, and prevention and treatment services; (4) strategic issues 
influencing the ability of CDC and HRSA to fulfill their missions; (5) 
development and implementation of federal programs focused on 
prevention and treatment; and (6) provide support to the agencies in 
their response to emerging health needs.
    Matters to be Considered: The agenda will include discussions on 
(1) syndemic approach to testing, (2) using prescription data to 
support the HIV care continuum, (3) HIV and aging, (4) an update on 
DoxyPEP, (5) advancing diagnosis of hepatitis C virus infection, (6) an 
update from the Long-Acting Injectable Workgroup, (7) an update from 
the Community Partnerships Workgroup, (8) an update from the

[[Page 14845]]

Workforce Workgroup, and (9) an update from the Presidential Advisory 
Council on HIV/AIDS. Agenda items are subject to change as priorities 
dictate.

Public Participation

    Written Public Comment: Members of the public are welcome to submit 
written comments in advance of the meeting. Written comments must be 
submitted by emailing [email protected] with subject line ``Spring 
CHAC Public Comment Registration'' by April 19, 2024.
    Oral Public Comment: Individuals who would like to make an oral 
comment during the public comment period must register by emailing 
[email protected] with subject line ``Spring CHAC Public Comment 
Registration'' by March 26, 2024. The public comment period is on April 
9, 2024, at 3:45 p.m., EDT.
    The Director, Office of Strategic Business Initiatives, Office of 
the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-04197 Filed 2-28-24; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.